{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:29:50Z","timestamp":1788557390888,"version":"build-2803163510"},"reference-count":32,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Transl Myol"],"abstract":"<jats:p>The aim of this study was to identify the efficacy of drug agents for pharmacological Treatment of Presbyopia. Published research papers were reviewed using the relevant terms in PubMed, Science direct, Google scholar, Medline, Google patent, Ovid, Cochrane Database of Systematic Reviews, Scopus. In the initial search, 2270 records were obtained. By removing duplicate articles and all articles that did not meet the inclusion criteria or were inappropriate due to indirect relevance to the subject, 44 studies were selected. It should be noted that all studies had inclusion criteria. There are a number of topical pharmacological agents available for treating presbyopia such as FOV Tears and PresbiDrop. They consist of parasympathetic agent and non-steroidal anti-inflammatory drugs (NSAIDs), to contract the ciliary and pupil muscle and restore the accommodation. Another example of topical pharmacological agent is EV06. It is a lens-softening eye drop which can affect the rigid lens in presbyopia. Currently there is no pharmacological agent available to treat presbyopia. Although there are limited number of peer-reviewed articles available, the outcome for future agents under investigation are promising.<\/jats:p>","DOI":"10.4081\/ejtm.2022.10781","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T06:17:35Z","timestamp":1663568255000},"source":"Crossref","is-referenced-by-count":28,"title":["Pharmacological treatment of presbyopia: A systematic review"],"prefix":"10.4081","volume":"32","author":[{"given":"Negin","family":"Haghpanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid","family":"Alany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"58963","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.04.014"},{"key":"58964","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2020.100885"},{"key":"58965","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0256"},{"key":"58966","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211631"},{"key":"58967","unstructured":"U.S. Census Bureau. International data base of world population by age and sex (year 2015 selected). [Internet].2016. [cited 28 Apr 2021] [about one page] https:\/\/www.census.gov\/population\/international\/data\/idb\/worldpop.php"},{"key":"58968","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-016-0050-x"},{"key":"58969","unstructured":"Encyclopedia M. Presbyopia: MedlinePlus Medical Encyclopedia [Internet]. Medlineplus.gov. 2021 [cited 2021 Mar 30]. https:\/\/medlineplus.gov\/ency\/article\/001026.htm"},{"key":"58970","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2019.8091"},{"key":"58971","unstructured":"Moorfields Eye Hospital to close its specials manufacturing facility. The Pharmaceutical Journal [Internet]. 2015; [cited 2021 Apr 26]; [about 1 page]. Presbyopia - Conditions - Moorfields Eye Hospital."},{"key":"58972","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000297"},{"key":"58973","unstructured":"Benozzi G, Perez C, Leiro J, Facal S, Orman B. Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study .Transl Vis Sci Technol [Internet]. June 2020 [cited 2021 Apr 26]; Vol.9, 25."},{"key":"58974","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_53_18"},{"key":"58975","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.03.005"},{"key":"58976","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12129"},{"key":"58977","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-017-0068-8"},{"key":"58978","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-018-0154-6"},{"key":"58979","unstructured":"Hernandez VR ,Diaz HC. Eurocanarias Oftalmologica. Ophthalmic composition for the correction of presbyopia. European Patent Office [Internet]. EP 2 886 113 A1.2015. March 30. [cited 2021 Apr 26] EP2886113A1 - Ophthalmic composition for the correction of presbyopia - Google Patents."},{"key":"58980","doi-asserted-by":"publisher","DOI":"10.4172\/2324-8599.1000218"},{"key":"58981","unstructured":"Benozzi JL. Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia. United State [Internet]. patent US 8,524,758 B2.2013. March 30. [cited 2021 Apr 26]. US8524758B2 - Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia - Google Patents"},{"key":"58982","unstructured":"Restrepo LFV, Ophthalmic formulation and method for ameliorating presbyopia. United State [Internet]. Patent US 2014\/0024642 A1. 2014.March 30. [cited 2021 Apr 26]. US20140024642A1 - Ophthalmic formulation and method for ameliorating presbyopia - Google Patents"},{"key":"58983","unstructured":"Claes G. Feinblaum, Patel S, \u0160alamun F. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration. WIPO(PCT) [Internet]. patent WO 2015\/122853 Al.2015.March 30. [cited 2021 Apr 26]. WO2015122853A1 - Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration - Google Patents"},{"key":"58984","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207449"},{"key":"58985","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000137"},{"key":"58986","unstructured":"Kaufman S. Addressing presbyopia pharmacologically. Ophthalmology Times. 2012. Available at https:\/\/www.ophthalmologytimes.com\/article\/addressing-presbyopia-pharmacologically. Last accessed February 8, 2022."},{"key":"58987","unstructured":"Benozzi, J, Benozzi, G, Orman B. Presbyopia: a New Potential Pharmacological Treatment. Med Hypothesis Discov Innov Ophthalmol [Internet]. 2012 [cited 2021 Apr 26] Spring; 1(1): 3\u20135. Presbyopia: a New Potential Pharmacological Treatment (nih.gov)."},{"key":"58988","unstructured":"Addressing presbyopia pharmacologically [Internet] 2021[cited 2021 Mar 30]. Ophthalmology Times. https:\/\/www.ophthal mologytimes.com\/ view\/addressing-presbyopia-pharmacologically."},{"key":"58989","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0065-3"},{"key":"58990","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01391-z"},{"key":"58991","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62436-7"},{"key":"58992","unstructured":"Gwon A ,EWoldeMussie. Allergan Inc Vision Pharmaceuticals LP. Cholinergic agents in the treatment of presbyopia. United State [Internet]. patent US 6,291,466 B1.2001 March 30. [cited 2021 Apr 26]. https:\/\/patents.google.com\/patent\/US6291466B1\/en"},{"key":"58993","doi-asserted-by":"publisher","DOI":"10.17925\/EOR.2017.11.02.99"},{"key":"58994","unstructured":"Abad JC. Allergan Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. United State [Internet]. patent US 2020\/0069651 A1.2020. March 30. [cited 2021 Apr 26]. US20200069651A1 - Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism - Google Patents."}],"container-title":["European Journal of Translational Myology"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/bam\/article\/download\/10781\/10327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/bam\/article\/download\/10781\/10327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T05:23:15Z","timestamp":1664428995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/bam\/article\/view\/10781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.4081\/ejtm.2022.10781","relation":{},"ISSN":["2037-7460","2037-7452"],"issn-type":[{"value":"2037-7460","type":"electronic"},{"value":"2037-7452","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}